Literature DB >> 17591965

Overexpression of the cytotoxic T cell (CT) carbohydrate inhibits muscular dystrophy in the dyW mouse model of congenital muscular dystrophy 1A.

Rui Xu1, Kumaran Chandrasekharan, Jung Hae Yoon, Marybeth Camboni, Paul T Martin.   

Abstract

A number of recent studies have demonstrated therapeutic effects of transgenes on the development of muscle pathology in the mdx mouse model for Duchenne muscular dystrophy, but none have been shown also to be effective in mouse models for laminin alpha2-deficient congenital muscular dystrophy (MDC1A). Here, we show that overexpression of the cytotoxic T cell (CT) GalNAc transferase (Galgt2) is effective in inhibiting the development of muscle pathology in the dy(W) mouse model of MDC1A, much as we had previously shown in mdx animals. Embryonic overexpression of Galgt2 in skeletal muscles using transgenic mice or postnatal overexpression using adeno-associated virus both reduced the extent of muscle pathology in dy(W)/dy(W) skeletal muscle. As with mdx mice, embryonic overexpression of the Galgt2 transgene in dy(W)/dy(W) myofibers inhibited muscle growth, whereas postnatal overexpression did not. Both embryonic and postnatal overexpression of Galgt2 in dy(W)/dy(W) muscle increased the expression of agrin, a protein that, in recombinant form, has been shown to ameliorate disease, whereas laminin alpha1, another disease modifier, was not expressed. Galgt2 over-expression also stimulated the glycosylation of a gly-colipid with the CT carbohydrate, and glycolipids accounted for most of the CT-reactive material in postnatal overexpression experiments. These experiments demonstrate that Galgt2 overexpression is effective in altering disease progression in skeletal muscles of dy(W) mice and should be considered as a therapeutic target in MDC1A.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591965      PMCID: PMC1941597          DOI: 10.2353/ajpath.2007.060927

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  100 in total

Review 1.  The congenital muscular dystrophies: recent advances and molecular insights.

Authors:  Jerry R Mendell; Daniel R Boué; Paul T Martin
Journal:  Pediatr Dev Pathol       Date:  2006 Nov-Dec

2.  rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice.

Authors:  Paul Gregorevic; James M Allen; Elina Minami; Michael J Blankinship; Miki Haraguchi; Leonard Meuse; Eric Finn; Marvin E Adams; Stanley C Froehner; Charles E Murry; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2006-07-02       Impact factor: 53.440

3.  Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy.

Authors:  Kinga I Gawlik; Jia-Yi Li; Asa Petersén; Madeleine Durbeej
Journal:  Hum Mol Genet       Date:  2006-08-07       Impact factor: 6.150

4.  Laminin alpha4 and integrin alpha6 are upregulated in regenerating dy/dy skeletal muscle: comparative expression of laminin and integrin isoforms in muscles regenerating after crush injury.

Authors:  L M Sorokin; M A Maley; H Moch; H von der Mark; K von der Mark; L Cadalbert; S Karosi; M J Davies; J K McGeachie; M D Grounds
Journal:  Exp Cell Res       Date:  2000-05-01       Impact factor: 3.905

5.  Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency.

Authors:  W Kuang; H Xu; J T Vilquin; E Engvall
Journal:  Lab Invest       Date:  1999-12       Impact factor: 5.662

6.  Distribution of ten laminin chains in dystrophic and regenerating muscles.

Authors:  B L Patton; A M Connoll; P T Martin; J M Cunningham; S Mehta; A Pestronk; J H Miner; J R Sanes
Journal:  Neuromuscul Disord       Date:  1999-10       Impact factor: 4.296

7.  Selective uptake and sustained expression of AAV vectors following subcutaneous delivery.

Authors:  B A Donahue; J G McArthur; S K Spratt; D Bohl; C Lagarde; L Sanchez; B A Kaspar; B A Sloan; Y L Lee; O Danos; R O Snyder
Journal:  J Gene Med       Date:  1999 Jan-Feb       Impact factor: 4.565

8.  New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins.

Authors:  E C Brinkman-Van der Linden; A Varki
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

9.  Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: evidence for a utrophin-independent mechanism.

Authors:  Rui Xu; Marybeth Camboni; Paul T Martin
Journal:  Neuromuscul Disord       Date:  2007-02-14       Impact factor: 4.296

10.  Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages.

Authors:  Sarina Meinen; Patrizia Barzaghi; Shuo Lin; Hanns Lochmüller; Markus A Ruegg
Journal:  J Cell Biol       Date:  2007-03-26       Impact factor: 10.539

View more
  36 in total

1.  Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle.

Authors:  Jung Hae Yoon; Eric Johnson; Rui Xu; Laura T Martin; Paul T Martin; Federica Montanaro
Journal:  J Proteome Res       Date:  2012-07-30       Impact factor: 4.466

2.  Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates.

Authors:  Louis G Chicoine; Louise R Rodino-Klapac; Guohong Shao; Rui Xu; William G Bremer; Marybeth Camboni; Bethannie Golden; Chrystal L Montgomery; Kimberly Shontz; Kristin N Heller; Danielle A Griffin; Sarah Lewis; Brian D Coley; Christopher M Walker; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Paul T Martin
Journal:  Mol Ther       Date:  2013-10-22       Impact factor: 11.454

3.  Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.

Authors:  Deborah A Zygmunt; Kelly E Crowe; Kevin M Flanigan; Paul T Martin
Journal:  Hum Gene Ther       Date:  2016-12-29       Impact factor: 5.695

4.  rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart.

Authors:  Rui Xu; Ying Jia; Deborah A Zygmunt; Paul T Martin
Journal:  Mol Ther       Date:  2019-01-15       Impact factor: 11.454

5.  Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone.

Authors:  Megan L Cramer; Guohong Shao; Louise R Rodino-Klapac; Louis G Chicoine; Paul T Martin
Journal:  Hum Gene Ther       Date:  2017-03-23       Impact factor: 5.695

6.  Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.

Authors:  Rui Xu; Neha Singhal; Yelda Serinagaoglu; Kumaran Chandrasekharan; Mandar Joshi; John A Bauer; Paulus M L Janssen; Paul T Martin
Journal:  Am J Pathol       Date:  2015-10       Impact factor: 4.307

7.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

8.  B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.

Authors:  Paul J Thomas; Rui Xu; Paul T Martin
Journal:  Am J Pathol       Date:  2016-09       Impact factor: 4.307

9.  The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.

Authors:  Jung Hae Yoon; Kumaran Chandrasekharan; Rui Xu; Matthew Glass; Neha Singhal; Paul T Martin
Journal:  Mol Cell Neurosci       Date:  2009-05-12       Impact factor: 4.314

10.  Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of alpha sarcoglycan-deficient mice.

Authors:  Rui Xu; Sarah DeVries; Marybeth Camboni; Paul T Martin
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.